Current and Future Strategies for Relapsed Neuroblastoma: Challenges on the Road to Precision Therapy

@article{Morgenstern2013CurrentAF,
  title={Current and Future Strategies for Relapsed Neuroblastoma: Challenges on the Road to Precision Therapy},
  author={Daniel A Morgenstern and Sylvain Baruchel and Meredith S Irwin},
  journal={Journal of Pediatric Hematology/Oncology},
  year={2013},
  volume={35},
  pages={337–347}
}
More than half of the patients with high-risk neuroblastoma (NB) will relapse despite intensive multimodal therapy, with an additional 10% to 20% refractory to induction chemotherapy. Management of these patients is challenging, given disease heterogeneity, resistance, and organ toxicity including poor hematological reserve. This review will discuss the current treatment options and consider novel therapies on the horizon. Cytotoxic chemotherapy regimens for relapse and refractory NB typically… Expand
Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk Neuroblastoma
TLDR
It was showed that the addition of conventional chemotherapy improved the quality of metastatic response only for the group of patients with partial response, so stratification criteria is proposed for those patients very unlikely to benefit from a plethora of additional lines of treatment, but might benefit from introduction of novel agents. Expand
Evidence for the efficacy of immunotherapy in children with high-risk neuroblastoma.
TLDR
Combined therapy with monoclonal antibodies, intravenous interleukin-2 (Il-2), intravenous granulocyte-macrophage colony-stimulating factor (GM-CSF) and oral 13-cis-retinoic acid have been proved to be effective in some randomised trials, but the long-term benefit of this treatment approach needs to be established. Expand
Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study
TLDR
Long-term PFS is possible for HR-NB patients who achieve at least a second CR/VGPR and receive consolidation that includes anti-GD2 immunotherapy plus isotretinoin, even if the patients received these biological treatments before relapse. Expand
Cancer stem cells in neuroblastoma therapy resistance
TLDR
This review presents the current understanding of NB-CSCs, their intrinsic role in tumorigenesis, their function in disease progression, and their influence on acquired therapy resistance and tumor evolution, and the development of a CSC-targeted therapeutic approach. Expand
Oxaliplatin and Doxorubicin for Relapsed or Refractory High-Risk Neuroblastoma
TLDR
In a cohort of heavily pretreated relapsed and refractory neuroblastoma patients, the combination of oxaliplatin and doxorubicin demonstrated anti-tumor activity and merits further investigation. Expand
Apatinib plus retinoic acid as maintenance for children with relapsed stage 4 high-risk neuroblastoma
TLDR
The outcomes from these cases suggest that apatinib plus isotretinoin might be an option for maintenance therapy in patients with recurrent high-risk NB. Expand
A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma
TLDR
There is no clear superior re-induction therapy for 1st relapse of HRNB, and Randomised controlled trials with separate arms for relapsed versus refractory disease are needed to determine optimal re-Induction chemotherapy to act as a backbone for testing newer targeted agents. Expand
Neuroblastoma: paradigm for precision medicine.
TLDR
Current clinical trials have continued to reduce therapy for patients with non-high-risk NB, including the most favorable subsets who are often followed with observation approaches, and high-risk patients are treated aggressively with chemotherapy, radiation, surgery, and myeloablative and immunotherapies. Expand
Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside
TLDR
It is demonstrated that combination of anti-O-acetyl GD2 monoclonal antibody 8B6 with topotecan synergistically inhibited neuroblastoma cell proliferation, as shown by the combination index values. Expand
De novo regulation of RD3 synthesis in residual neuroblastoma cells after intensive multi-modal clinical therapy harmonizes disease evolution
TLDR
Whether RD3 loss is an acquired process in cells that survive intensive multi-modal clinical therapy (IMCT) and its significance in disease evolution is investigated and profound reductions in RD3 transcription indicate the de novo regulation of RD3 synthesis in resistant cells after IMCT. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 151 REFERENCES
New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome
TLDR
Rational development of novel approaches to neuroblastoma therapy requires forward-thinking strategies to unequivocally prove activity in the relapse setting and, ultimately, efficacy in curing patients when integrated into frontline treatment plans. Expand
Neuroblastoma: Therapeutic strategies for a clinical enigma.
TLDR
Neuroblastoma is the first pediatric cancer for which monoclonal-antibody-based immunotherapy has been shown to be effective, particularly for metastatic osteomedullary disease, and efforts are under way to refine and enhance antibody-based Immunotherapy and to determine its optimal use. Expand
Disialoganglioside Directed Immunotherapy of Neuroblastoma
TLDR
The advent of highly sensitive and specific molecular assays to measure MRD has confirmed the efficacy anti-GD2 antibody immunotherapy in patients with subclinical disease and will allow further optimization of other anti-MRD therapies. Expand
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
TLDR
Follow-up analysis of the patient cohort indicated that immunotherapy with MAB ch14.18 may prevent late relapses and metronomic oral maintenance chemotherapy also appeared effective. Expand
Promising Therapeutic Targets in Neuroblastoma
TLDR
A recently approved small-molecule inhibitor of ALK has shown promising preclinical activity for neuroblastoma and is currently in phase I and II trials, the first agent directed to a specific mutation in Neuroblastoma, and marks a new step toward personalized therapy for neuro Blastoma. Expand
New therapeutic targets for the treatment of high‐risk neuroblastoma
High‐risk neuroblastoma remains a major problem in pediatric oncology, accounting for 15% of childhood cancer deaths. Although incremental improvements in outcome have been achieved with theExpand
Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma
TLDR
Current investigations focus on overcoming resistance by elucidating the molecular/genetic causes of neuroblastoma tumorigenesis and progression, with the aim of developing more effective biologically targeted therapies for this disease. Expand
Complete Remission Following Decitabine/Dendritic Cell Vaccine for Relapsed Neuroblastoma
TLDR
The outcome of the first patient treated in a phase 1 study for relapsed neuroblastoma, using the chemotherapy agent decitabine to upregulate cancer testis antigen expression, followed by a dendritic cell vaccine targeting the cancertestis antigens MAGE-A1, Mage-A3, and NY-ESO-1 is reported. Expand
Targeting ALK in neuroblastoma—preclinical and clinical advancements
TLDR
The biology ofALK in the development of neuroblastoma, preclinical and clinical progress with the use of ALK inhibitors and immunotherapy, challenges associated with resistance to such therapies and the steps being taken to overcome some of these hurdles are discussed. Expand
Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study.
  • H. Rubié, J. Chisholm, +17 authors G. Vassal
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
Temozolomide shows activity in heavily pretreated patients with NB, and deserves further evaluation in combination with another drug. Expand
...
1
2
3
4
5
...